Daiichi Sankyo Pays $39m To Settle U.S. Kickback Allegations
This article was originally published in PharmAsia News
Executive Summary
The U.S. subsidiary of major Japanese company Daiichi Sankyo has agreed to pay a $39 million fine, plus fees and costs, to the U.S. Government and state Medicaid programs in a civil settlement to resolve allegations it paid kickbacks designed to induce physicians to prescribe certain of its drugs.